Pharma

Your Article Summary

See Latest Articles

Update on Eloxatin (oxaliplatin) U.S. Patent Litigation
Sanofi-aventis, 06/19/09

Sanofi-aventis has learned that the U.S. District Court for the District of New Jersey has ruled against the Group by granting summary judgment motions brought by certain generic companies in the U.S. Eloxatin patent litigation. Sanofi-aventis intends to appeal this decision.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

New study results presented at 2009 san antonio breast cancer symposium show importance of protecting your bones
Amgen, 12/11/09

Phase III CONFIRM study shows FASLODEX (fulvestrant) Injection 500 mg may delay time of disease progression over 250-mg dose in postmenopausal women with hormone receptor-positive advanced breast cancer
AstraZeneca, 12/11/09

Salix Pharmaceuticals Reports Concurrence with FDA on Content and Format of the Pending Rifaximin NDA in the Treatment of Non-Constipation Irritable Bowel Syndrome
Salix Pharmaceuticals, 12/11/09

 See all of Research & Development